文献速递白血病

微滴数字PCR检测儿童急性髓系白血病KIT D816V微小克隆

Droplet digital polymerase chain reaction assay for the detection of the minor clone of KIT D816V in paediatric acute myeloid leukaemia especially showing RUNX1-RUNX1T1 transcripts.
PubMed 文献 · Br J Haematol · 2021-06-13

该研究采用微滴数字PCR方法检测335例儿童急性髓系白血病患者初诊时KIT D816V微小克隆,共发现24例突变(7.2%),其中12例仅经数字PCR检出且均属核心结合因子AML。KIT D816V突变组5年无事件生存率显著低于无突变组(44.1% vs 74.7%,P=0.02),但5年总生存率无差异。

要点

  • 数字PCR可检出常规方法漏检的KIT D816V微小克隆。
  • KIT D816V突变与儿童CBF-AML不良无事件生存相关。
  • KIT D816V可能是RUNX1-RUNX1T1阳性AML的复发风险因素。

核心结论

  • 在儿童CBF-AML中确认了KIT D816V微小克隆的存在,KIT D816V被认为是RUNX1-RUNX1T1阳性AML患者的复发风险因素。

研究设计与样本

  • 回顾性检测335例儿童急性髓系白血病患者初诊样本中KIT D816V突变,采用微滴数字PCR方法检测微小克隆并分析预后意义。

主要发现

  • 335例儿童患者中鉴定出24例KIT D816V突变(7.2%),其中12例仅通过数字PCR方法检出,且这12例均局限于核心结合因子AML患者。
  • KIT D816V突变患者5年无事件生存率显著低于无突变患者(44.1% [95%CI 16.0%-69.4%] vs 74.7% [95%CI 63.0%-83.2%],P=0.02)。
  • 两组5年总生存率无显著差异(92.9% [95%CI 59.0%-NA] vs 89.7% [95%CI 69.6%-96.8%],P=0.607)。

关键数值与推荐

  • KIT D816V突变检出率7.2%(24/335例儿童AML患者)。
  • KIT D816V突变组5年无事件生存率44.1%(95%CI 16.0%-69.4%),无突变组74.7%(95%CI 63.0%-83.2%),P=0.02。
  • KIT D816V突变组5年总生存率92.9%(95%CI 59.0%-NA),无突变组89.7%(95%CI 69.6%-96.8%),P=0.607。

临床怎么用

  • 对儿童CBF-AML尤其是RUNX1-RUNX1T1阳性患者,可考虑采用数字PCR检测KIT D816V微小克隆以辅助风险评估。
  • KIT D816V突变提示复发风险增高,但总生存无差异,需结合其他指标综合判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KIT D816V mutation within exon 17 has been particularly reported as one of the poor prognostic factors in pediatric acute myeloid leukemia (AML) with RUNX1-RUNX1T1. The exact frequency and the prognostic impact of KIT D816V minor clones at diagnosis were not examined. In this study, the minor clones were examined and the prognostic significance of KIT D816V mutation in pediatric patients was investigated. Consequently, 24 KIT D816V mutations (7.2%) in 335 pediatric patients were identified, and 12 of 24 were only detected via the digital droplet polymerase chain reaction method. All 12 patients were confined in core binding factor (CBF)-AML patients. The 5 year event-free survival of the patients with KIT D816V mutation was significantly inferior to those without KIT D816V mutation (44.1% [95% confidence interval (CI), 16.0%-69.4%] vs. 74.7% [95% CI, 63.0%-83.2%] P-value = 0.02, respectively). The 5 year overall survival was not different between the two groups (92.9% [95% CI, 59.0%-NA vs. 89.7% [95% CI, 69.6%-96.8%] P-value = 0.607, respectively). In this study, KIT D816V minor clones in patients with CBF-AML were confirmed and KIT D816V was considered as a risk factor for relapse in patients with RUNX1-RUNX1T1-positive AML.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Sasaki K, Tsujimoto S, Miyake M, et al. Droplet digital polymerase chain reaction assay for the detection of the minor clone of KIT D816V in paediatric acute myeloid leukaemia especially showing RUNX1-RUNX1T1 transcripts. Br J Haematol. 2021. PMID: 34120331. doi:10.1111/bjh.17569

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。